BioMimetix Announces Publication of Phase I/II Clinical Trial Evaluating BMX-001 in Patients With Locally Advanced Head and Neck Cancer
Results demonstrate a favorable safety profile and reduction of treatment-related toxicities during chemoradiation therapy
ENGLEWOOD, Colo., Nov. 19, 2026 /PRNewswire/ -- BioMimetix JV, LLC today announced the publication of results from a NCI funded multicenter Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).
The study found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.
The results have been published in the International Journal of Radiation Oncology, Biology, Physics.
"The reduction of treatment-related toxicities is a major and elusive challenge in the management of head and neck cancer," said David M. Brizel, MD, Principal Investigator of the study. "These findings suggest that BMX-001 will reduce the severity of these toxicities while maintaining the effectiveness of chemoradiation therapy."
Key Study Findings
This single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy.
Key results included:
- Favorable safety profile, with only one patient experiencing serious adverse events possibly related to BMX-001
- No Grade 4 cases of severe oral mucositis were observed. Grade 3 severe oral mucositis was delayed in onset and occurred in only 41.4% of patients
- Rates of xerostomia were low, with long term Grade ≥ 2 events occurring in only 9.1% of subjects
- At a median follow-up of 24 months, 96.6% of patients were alive without disease progression
- Administration of BMX-001 showed a profound positive impact on quality of life with many measures returning to baseline by six months.
Study Background
Radiation therapy and chemotherapy induce oxidative stress that contributes to treatment-related toxicities such as oral mucositis and xerostomia which significantly impair patients' quality of life and treatment adherence.
BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumor cell growth because of the unique metabolic pathways active in tumors. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumor responses to treatment.
This study represents a multi-institutional Phase I/II clinical trial of BMX-001 evaluating its safety, tolerability and efficacy in patients receiving concurrent chemoradiation for head and neck cancer.
Continued Development
"These results support the continued development of BMX-001 as a therapy to improve the efficacy and tolerability of radiation therapy in many different solid tumors," said James Crapo, MD CEO of BioMimetix. "Reducing treatment-related toxicities while preserving anti-tumor efficacy represent a unique and important step that will improve outcomes for patients with head and neck cancer."
BMX-001 is being investigated in additional clinical studies across multiple cancer types. BMX-001 is currently being evaluated in a randomized Phase II clinical trial (NRG-CC013; ClinicalTrials.gov Identifier: NCT06532279) conducted through the National Cancer Institute - supported by NRG Oncology, a Network Group in the NCI National Clinical Trials Network, to further assess its potential to reduce treatment-related toxicities in patients receiving chemoradiation for head and neck cancer.
About BMX-001
BMX-001 (MnTnBuOE-2-PyP⁵⁺) is a redox-active manganese metalloporphyrin compound that mimics the activity of superoxide dismutase enzymes and modulates oxidative stress pathways such as NFkB and HIF-1a. The compound has demonstrated potential to protect normal tissues from radiation-induced injury while maintaining or enhancing tumor response to radiation therapy with or without chemotherapy.
About BioMimetix
BioMimetix JV LLC is a biotechnology company focused on developing novel redox-active therapeutics designed to improve the effectiveness and tolerability of radiation therapy and other cancer treatments.
Forward-Looking Statements and Disclosures
This press release contains forward-looking statements regarding the development and potential therapeutic benefits of BMX-001. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially from those anticipated. BMX-001 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration. BioMimetix undertakes no obligation to update forward-looking statements except as required by law.
BioMimetix is a privately held biotechnology company that licensed the intellectual property underlying BMX-001 from Duke University.
Read the full article:
A Phase I/II Trial of the Metalloporphyrin Radioprotectant BMX-001 in Patients with Newly Diagnosed Head and Neck Cancer Receiving Concurrent Radiation Therapy and Cisplatin - ScienceDirect
DOI: 10.1016/j.ijrobp.2026.11.001
Media Contact:
Robert Hellewell
BioMimetix JV LLC
[email protected]
202.415.4931
SOURCE BioMimetix Pharmaceuticals

Share this article